Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study.

Eur J Cancer Prev

aDepartment of Public Health, Area Vasta Emilia Centrale Cancer Registry, Ferrara Local Health Unit bDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara cDepartment of Public Health, Area Vasta Emilia Centrale Cancer Registry, Bologna Local Health Unit, Bologna dClinical Oncology Unit, Department of Specialty Medicine, University Hospital Ferrara, Ferrara, Italy eDepartment of Biostatistics, University Hospital of Lyon fUniversity of Lyon, Lyon gUniversity of Lyon 1 hCNRS, UMR 5558,Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department iFrench Network of Cancer Registries (Francim), Toulouse jBas-Rhin Cancer Registry, Department of Epidemiology and Public Health, EA 3430, Faculty of Medicine, University of Strasbourg kDepartment of Public Health, University Hospital of Strasbourg, Strasbourg lRegistre Bourguignon des Cancers Digestifs, CHU de Dijon; INSERM U 866; University of Burgundy, Dijon, France mRegistro Tumori del Canton Ticino, Istituto cantonale di patologia, Locarno, Switzerland.

Published: January 2017

Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess-rate modeling strategy. There were little differences between the six countries in the 5-year age-standardized net survival (2000-2004): it ranged from 13% (France and Portugal) to 16% (Belgium). An increase in the net age-standardized survival was observed in all countries between 1992 and 2004, both at 1 year and at 5 years (the highest in Spain, the lowest in France). Generally, patients aged 60 years showed the highest increase. There was a progressive decrease in EMR over the 5-year- period following diagnosis. The study confirmed the poor prognosis of liver cancer. Innovative treatments might improve the prognosis as well as preventive screening of cirrhotic patients with good liver function. Efforts are also needed to improve registration practices.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0000000000000298DOI Listing

Publication Analysis

Top Keywords

net survival
20
liver cancer
16
trends net
8
survival liver
8
cancer european
8
european latin
8
latin countries
8
france italy
8
spain switzerland
8
trend analyses
8

Similar Publications

Background: Atrial fibrillation (AF) is the most prevalent arrhythmia encountered in clinical practice. Triglyceride glucose index (Tyg), a convenient evaluation variable for insulin resistance, has shown associations with adverse cardiovascular outcomes. However, studies on the Tyg index's predictive value for adverse prognosis in patients with AF without diabetes are lacking.

View Article and Find Full Text PDF

The optimal duration of on-scene cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest (OHCA) patients remains uncertain. Determining this critical time period requires outweighing the potential risks associated with intra-arrest transport while minimizing delays in accessing definitive hospital-based treatments. This study evaluated the association between on-scene CPR duration and 30-day neurologically favorable survival based on the transport time interval (TTI) in patients with OHCA.

View Article and Find Full Text PDF

Objective: We aimed to develop a highly interpretable and effective, machine-learning based risk prediction algorithm to predict in-hospital mortality, intubation and adverse cardiovascular events in patients hospitalised with COVID-19 in Australia (AUS-COVID Score).

Materials And Methods: This prospective study across 21 hospitals included 1714 consecutive patients aged ≥ 18 in their index hospitalization with COVID-19. The dataset was separated into training (80%) and test sets (20%).

View Article and Find Full Text PDF

Introduction: Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP-ribose) polymerase inhibitors. We analyzed real-world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring germline BRCA mutations in Italy, where olaparib is not reimbursed for this indication.

Methods: Clinico/pathological data of pancreatic cancer patients with documented BRCA1-2 germline pathogenic variants who had received first-line chemotherapy for metastatic disease were collected from 23 Italian oncology departments and the impact of olaparib exposure on overall survival (OS) was analyzed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!